Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Curis, Inc. stock logo
CRIS
Curis
$2.04
+2.0%
$1.81
$1.02
$11.46
$21.34M3.6570,831 shs45,823 shs
Dominari Holdings Inc. stock logo
DOMH
Dominari
$4.68
+1.7%
$4.63
$0.83
$13.58
$68.53M0.591.25 million shs237,291 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.83
+2.8%
$1.64
$1.33
$2.89
$54.11M1.85406,060 shs195,438 shs
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$1.78
-1.7%
$1.55
$1.00
$5.01
$16.54M0.4765,987 shs47,360 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Curis, Inc. stock logo
CRIS
Curis
+2.00%-3.77%+25.15%-34.62%-81.79%
Dominari Holdings Inc. stock logo
DOMH
Dominari
+1.74%-11.03%-2.30%-43.75%+114.68%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
+2.81%+4.57%+11.59%+14.38%-2.14%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-1.66%-3.40%+1.71%+1.71%-34.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Curis, Inc. stock logo
CRIS
Curis
2.9795 of 5 stars
3.55.00.00.02.80.01.3
Dominari Holdings Inc. stock logo
DOMH
Dominari
1.5534 of 5 stars
0.04.00.00.03.12.50.6
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.1588 of 5 stars
3.50.00.00.02.83.30.6
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
3.1781 of 5 stars
3.53.00.00.03.81.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Curis, Inc. stock logo
CRIS
Curis
3.00
Buy$17.00733.33% Upside
Dominari Holdings Inc. stock logo
DOMH
Dominari
0.00
N/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$21.001,047.54% Upside
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
3.00
Buy$12.20585.39% Upside

Current Analyst Ratings Breakdown

Latest CRIS, DOMH, FBIO, and SABS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Curis, Inc. stock logo
CRIS
Curis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$17.00
5/15/2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/14/2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
4/1/2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $20.00
4/1/2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
3/31/2025
Curis, Inc. stock logo
CRIS
Curis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $16.00
3/11/2025
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $16.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Curis, Inc. stock logo
CRIS
Curis
$11.20M1.91N/AN/A$3.34 per share0.61
Dominari Holdings Inc. stock logo
DOMH
Dominari
$24.89M2.75N/AN/A$9.90 per share0.47
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$57.78M0.94N/AN/A$0.10 per share18.30
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$2.24M7.38N/AN/A$6.21 per share0.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Curis, Inc. stock logo
CRIS
Curis
-$47.41M-$6.23N/AN/AN/A-443.35%-923.37%-78.35%8/7/2025 (Estimated)
Dominari Holdings Inc. stock logo
DOMH
Dominari
-$22.88M-$4.50N/AN/A-180.22%-32.89%-29.47%8/6/2025 (Estimated)
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$60.64M-$2.23N/AN/AN/A-84.53%N/A-34.93%8/12/2025 (Estimated)
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-$42.19M-$3.70N/AN/AN/A-1,450.14%-94.37%-67.26%8/14/2025 (Estimated)

Latest CRIS, DOMH, FBIO, and SABS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-$1.00-$0.56+$0.44-$0.56$0.13 millionN/A
5/6/2025Q1 2025
Curis, Inc. stock logo
CRIS
Curis
-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 million
4/15/2025Q4 2024
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/A$0.20N/A$0.20N/A$6.56 million
3/31/2025Q4 2024
Curis, Inc. stock logo
CRIS
Curis
-$1.36-$1.25+$0.11-$1.25$2.04 million$2.70 million
3/31/2025Q4 2024
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$0.79-$0.26+$0.53-$0.26$16.30 million$15.12 million
3/28/2025Q4 2024
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-$1.16-$1.23-$0.07-$1.23$0.12 million$0.05 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Curis, Inc. stock logo
CRIS
Curis
N/AN/AN/AN/AN/A
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Curis, Inc. stock logo
CRIS
Curis
N/A
1.22
1.22
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/A
10.25
10.25
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/A
1.23
1.06
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
0.09
3.69
3.69

Institutional Ownership

CompanyInstitutional Ownership
Curis, Inc. stock logo
CRIS
Curis
29.97%
Dominari Holdings Inc. stock logo
DOMH
Dominari
42.48%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
7.82%

Insider Ownership

CompanyInsider Ownership
Curis, Inc. stock logo
CRIS
Curis
5.45%
Dominari Holdings Inc. stock logo
DOMH
Dominari
32.98%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
33.40%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
26.46%
CompanyEmployeesShares OutstandingFree FloatOptionable
Curis, Inc. stock logo
CRIS
Curis
6010.46 million7.98 millionNo Data
Dominari Holdings Inc. stock logo
DOMH
Dominari
414.64 million4.01 millionNot Optionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17029.57 million18.39 millionOptionable
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
1409.29 million6.79 millionNot Optionable

Recent News About These Companies

Q2 Earnings Estimate for SABS Issued By HC Wainwright
SAB Biotherapeutics price target lowered to $20 from $25 at Chardan
SAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics (SABS) Gets a Buy from Craig-Hallum

New MarketBeat Followers Over Time

Media Sentiment Over Time

Curis stock logo

Curis NASDAQ:CRIS

$2.04 +0.04 (+2.00%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.02 -0.02 (-0.93%)
As of 05/27/2025 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Dominari stock logo

Dominari NASDAQ:DOMH

$4.68 +0.08 (+1.74%)
As of 05/27/2025 04:00 PM Eastern

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$1.83 +0.05 (+2.81%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.83 0.00 (-0.05%)
As of 06:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

SAB Biotherapeutics stock logo

SAB Biotherapeutics NASDAQ:SABS

$1.78 -0.03 (-1.66%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.97 +0.19 (+10.67%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.